EP0003089B1 - Séchoir pour feuilles imprimées par sérigraphie - Google Patents

Séchoir pour feuilles imprimées par sérigraphie Download PDF

Info

Publication number
EP0003089B1
EP0003089B1 EP19780400265 EP78400265A EP0003089B1 EP 0003089 B1 EP0003089 B1 EP 0003089B1 EP 19780400265 EP19780400265 EP 19780400265 EP 78400265 A EP78400265 A EP 78400265A EP 0003089 B1 EP0003089 B1 EP 0003089B1
Authority
EP
European Patent Office
Prior art keywords
hurdle
conveyor
sheet
clips
bent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
EP19780400265
Other languages
German (de)
English (en)
French (fr)
Other versions
EP0003089A1 (fr
Inventor
Bernard David
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Silium Francaise A Responsabilite Ltee Ste
Original Assignee
Silium Francaise A Responsabilite Ltee Ste
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9203176&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP0003089(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Silium Francaise A Responsabilite Ltee Ste filed Critical Silium Francaise A Responsabilite Ltee Ste
Publication of EP0003089A1 publication Critical patent/EP0003089A1/fr
Application granted granted Critical
Publication of EP0003089B1 publication Critical patent/EP0003089B1/fr
Expired legal-status Critical Current

Links

Images

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B41—PRINTING; LINING MACHINES; TYPEWRITERS; STAMPS
    • B41F—PRINTING MACHINES OR PRESSES
    • B41F23/00—Devices for treating the surfaces of sheets, webs, or other articles in connection with printing
    • B41F23/04—Devices for treating the surfaces of sheets, webs, or other articles in connection with printing by heat drying, by cooling, by applying powders
    • B41F23/044—Drying sheets, e.g. between two printing stations
    • B41F23/0443—Drying sheets, e.g. between two printing stations after printing
    • B41F23/0446—Wicket conveyors
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F26—DRYING
    • F26B—DRYING SOLID MATERIALS OR OBJECTS BY REMOVING LIQUID THEREFROM
    • F26B15/00—Machines or apparatus for drying objects with progressive movement; Machines or apparatus with progressive movement for drying batches of material in compact form
    • F26B15/02—Machines or apparatus for drying objects with progressive movement; Machines or apparatus with progressive movement for drying batches of material in compact form with movement in the whole or part of a circle
    • F26B15/08—Machines or apparatus for drying objects with progressive movement; Machines or apparatus with progressive movement for drying batches of material in compact form with movement in the whole or part of a circle in a vertical plane
    • F26B15/085—Machines or apparatus for drying objects with progressive movement; Machines or apparatus with progressive movement for drying batches of material in compact form with movement in the whole or part of a circle in a vertical plane with endless clamp or tray conveyor, e.g. wicket conveyor

Definitions

  • the present invention relates to a dryer for sheets printed by screen printing.
  • the drying of the sheets printed by screen printing is done at present, either manually by stacking on each other drying racks on each of which is placed a sheet, or mechanically by means of dryers in which blows air on the moving leaves.
  • a first known type of embodiment is thus constituted by a rectilinear tunnel inside which a rotating conveyor is arranged, an infrared or other heating device being additionally placed in the tunnel in association with an air ventilation system. Leaving the tunnel, the leaves are dry and are removed from the machine.
  • a second known type of embodiment consists of an endless conveyor rotating around axes placed at its ends, and which carries racks on which the printed sheets are placed.
  • This type of dryer is as long as the forced air tunnels, because only a very weak or no air flow allows only the laid leaves to stay in place.
  • Another disadvantage of this type of dryer is that the insufficiently rigid sheets touch the previous rack, which limits the possibility of use.
  • GB-A-793 216 describes a dryer without racks, in which the sheets are dried by blowing hot air flat on a table located in the upper part of the dryer.
  • the absence of racks is very annoying since the leaves can come to press against each other during their movement.
  • the insertion of the sheets into the tongs and their unloading are done in two separate consecutive operations.
  • This conveyor 1 is carried by a frame 5 in the middle of which is arranged a device 6 for blowing air of a type known per se.
  • Each series of pliers 9 is constituted, in the example shown, by a row of bent blades 12 (FIG. 3), rotatably mounted around axes or pins 13 parallel to the adjoining side of the rack 7, secured to the endless conveyor 1
  • the blades 12, preferably metallic, are bent in the example shown by forming an angle of approximately 120 degrees, the axes 13 being placed inside this angle, and supporting the blades 12 by means of ears 14 integral with the blades and in which the pins 13 are threaded.
  • the mooring device constituted by the clamps according to the invention, it is possible to ventilate with increased force, the sheets dry more quickly.
  • a lower number of racks is necessary to dry a determined quantity of sheets in a given time interval, which makes it possible to reduce the size of the machine by reducing the number of racks which it can contain.
  • the automatic opening and closing device can be produced in any other way equivalent to that described and shown in FIG. 3, for example by having fixed cams roughly similar to the heads 17 and on which the clamps would come. '' open when reaching horizontal.

Landscapes

  • Engineering & Computer Science (AREA)
  • Mechanical Engineering (AREA)
  • General Engineering & Computer Science (AREA)
  • Drying Of Solid Materials (AREA)
  • Supply, Installation And Extraction Of Printed Sheets Or Plates (AREA)
EP19780400265 1978-01-06 1978-12-27 Séchoir pour feuilles imprimées par sérigraphie Expired EP0003089B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR7800305 1978-01-06
FR7800305A FR2413974A1 (fr) 1978-01-06 1978-01-06 Sechoir pour feuilles imprimees par serigraphie

Publications (2)

Publication Number Publication Date
EP0003089A1 EP0003089A1 (fr) 1979-07-25
EP0003089B1 true EP0003089B1 (fr) 1981-08-12

Family

ID=9203176

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19780400265 Expired EP0003089B1 (fr) 1978-01-06 1978-12-27 Séchoir pour feuilles imprimées par sérigraphie

Country Status (3)

Country Link
EP (1) EP0003089B1 (ja)
DE (1) DE2860970D1 (ja)
FR (1) FR2413974A1 (ja)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7674605B2 (en) 2006-06-07 2010-03-09 Bioalliance C.V. Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same
US8030023B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. Nucleic acid encoding DR5 antibodies and uses thereof
US8691918B2 (en) 2010-05-17 2014-04-08 Emd Millipore Corporation Stimulus responsive polymers for the purification of biomolecules
US8697386B2 (en) 2009-10-22 2014-04-15 Genentech, Inc. Methods and compositions for modulating hepsin activation of macrophage-stimulating protein
US8771966B2 (en) 2010-06-03 2014-07-08 Genentech, Inc. Immuno-PET imaging of antibodies and immunoconjugates and uses therefor
US8999702B2 (en) 2008-06-11 2015-04-07 Emd Millipore Corporation Stirred tank bioreactor
US9266948B2 (en) 2009-12-23 2016-02-23 Genentech, Inc. Anti-Bv8 antibodies and uses thereof
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
US9873742B2 (en) 2012-10-05 2018-01-23 Genentech, Inc. Methods for diagnosing and treating inflammatory bowel disease

Families Citing this family (417)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5708142A (en) 1994-05-27 1998-01-13 Genentech, Inc. Tumor necrosis factor receptor-associated factors
US6030945A (en) * 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
US20050089958A1 (en) * 1996-01-09 2005-04-28 Genentech, Inc. Apo-2 ligand
US6998116B1 (en) 1996-01-09 2006-02-14 Genentech, Inc. Apo-2 ligand
JP2000507829A (ja) 1996-04-01 2000-06-27 ジェネンテック インコーポレーテッド Ａｐｏ―２ｌｉおよびａｐｏ―３アポトーシスポリペプチド
US5851984A (en) * 1996-08-16 1998-12-22 Genentech, Inc. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
US6159462A (en) * 1996-08-16 2000-12-12 Genentech, Inc. Uses of Wnt polypeptides
US6462176B1 (en) 1996-09-23 2002-10-08 Genentech, Inc. Apo-3 polypeptide
US6136958A (en) 1996-09-30 2000-10-24 Genentech, Inc. Antibodies to vertebrate smoothened proteins
US5990281A (en) 1996-09-30 1999-11-23 Genentech, Inc. Vertebrate smoothened proteins
CA2277266A1 (en) 1997-01-31 1998-08-06 Genentech, Inc. O-fucosyltransferase
WO1999060127A2 (en) 1998-05-15 1999-11-25 Genentech, Inc. Il-17 homologous polypeptides and therapeutic uses thereof
WO1999021999A2 (en) 1997-10-29 1999-05-06 Genentech, Inc. Wnt-1 inducible genes
WO1999027098A2 (en) 1997-11-21 1999-06-03 Genentech, Inc. A-33 related antigens and their pharmacological uses
PT998486E (pt) 1997-06-13 2007-08-21 Genentech Inc ''recuperação de proteínas por cromatografia seguida de filtração numa camada carregada''
EP1015587B1 (en) 1997-09-18 2008-04-23 Genentech, Inc. DcR3 POLYPEPTIDE, A TNFR HOMOLOG
JP2001522584A (ja) 1997-10-10 2001-11-20 ジェネンテク・インコーポレイテッド Ａｐｏ−３リガンドポリペプチド
US7192589B2 (en) 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
NZ527900A (en) 1997-12-03 2005-02-25 Genentech Inc PRO361 polypeptides and nucleic acids with homology to mucin and chitinase
EP1947119A3 (en) 1997-12-12 2012-12-19 Genentech, Inc. Treatment of cancer with anti-erb2 antibodies in combination with a chemotherapeutic agent
DE69939732D1 (de) 1998-01-15 2008-11-27 Genentech Inc Apo-2 ligand
EP1950300A3 (en) 1998-11-18 2011-03-23 Genentech, Inc. Antibody variants with higher binding affinity compared to parent antibodies
EP2075335A3 (en) 1998-12-22 2009-09-30 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
EP2330198A1 (en) 1998-12-23 2011-06-08 Genentech, Inc. IL-1 related polypeptides
KR101155191B1 (ko) 1999-01-15 2012-06-13 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
EP1953173B1 (en) 1999-06-15 2009-11-18 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids endoding the same
IL146954A0 (en) 1999-06-25 2002-08-14 Genentech Inc HUMANIZED ANTI-ErbB2 ANTIBODIES AND TREATMENT WITH ANTI-ErbB2 ANTIBODIES
PL202369B1 (pl) 1999-08-27 2009-06-30 Genentech Inc Zastosowanie przeciwciała skierowanego przeciw ErbB2, zastosowanie przeciwciała skierowanego przeciw ErbB oraz zestaw zawierający to przeciwciało
EP1690872A3 (en) 1999-12-01 2006-08-23 Genentech, Inc. Composition and methods for the diagnosis of tumours
EP1897944B1 (en) 1999-12-23 2011-08-10 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
ES2323220T3 (es) 2000-01-13 2009-07-09 Genentech, Inc. Polipeptidos humanos stra6.
US6740520B2 (en) 2000-03-21 2004-05-25 Genentech, Inc. Cytokine receptor and nucleic acids encoding the same
EP2792747A1 (en) 2000-06-23 2014-10-22 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
CA2648051A1 (en) 2000-06-23 2002-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
JP2004509078A (ja) 2000-07-27 2004-03-25 ジェネンテック・インコーポレーテッド Ａｐｏ−２ＬレセプターアゴニストとＣＰＴ−１１の相乗作用
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
DE60136281D1 (de) 2000-08-24 2008-12-04 Genentech Inc Methode zur inhibierung von il-22 induziertem pap1
EP1944317A3 (en) 2000-09-01 2008-09-17 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
DE60139944D1 (de) 2000-10-12 2009-10-29 Genentech Inc Niederviskose konzentrierte proteinformulierungen
US20020159996A1 (en) 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US7087726B2 (en) 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
WO2002096458A1 (en) 2001-05-30 2002-12-05 Genentech, Inc. Anti-ngf antibodies for the treatment of various disorders
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
KR100628425B1 (ko) 2001-06-20 2006-09-28 제넨테크, 인크. 종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
ES2386346T3 (es) 2001-08-29 2012-08-17 Genentech, Inc. Ácidos nucleicos y polipéptidos Bv8 con actividad mitógena
AU2002330015B2 (en) 2001-09-18 2008-02-07 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
BRPI0214168B8 (pt) 2001-11-14 2021-05-25 Centocor Inc anticorpos anti-il-6, moléculas de ácido nucleico codificando os mesmos, vetores compreendendo as referidas moléculas, composições e formulações compreendendo os referidos anticorpos, bem como métodos de produção dos mesmos
JP4063769B2 (ja) 2001-12-28 2008-03-19 中外製薬株式会社 タンパク質安定化方法
CA2471431A1 (en) 2002-01-02 2003-07-17 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7452675B2 (en) 2002-01-25 2008-11-18 The Queen's Medical Center Methods of screening for TRPM4b modulators
JP2005535290A (ja) 2002-02-22 2005-11-24 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための組成物と方法
WO2003072740A2 (en) 2002-02-25 2003-09-04 Genentech, Inc. Novel type-1 cytokine receptor glm-r
EP2305710A3 (en) 2002-06-03 2013-05-29 Genentech, Inc. Synthetic antibody phage libraries
EP2263691B1 (en) 2002-07-15 2012-08-29 F.Hoffmann-La Roche Ag Treatment of cancer with the recombinant humanized monoclonal anti-erbb2 antibody 2C4 (rhuMAb 2C4)
JP2006521082A (ja) 2002-09-11 2006-09-21 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための新規組成物と方法
AU2003265994B2 (en) 2002-09-11 2010-04-01 Genentech, Inc. Protein purification
US20070010434A1 (en) 2002-09-16 2007-01-11 Genetech, Inc. Novel compositions and methods for the treatment of immune related diseases
AU2003279084A1 (en) 2002-09-25 2004-04-19 Genentech, Inc. Novel compositions and methods for the treatment of psoriasis
EP2322201A3 (en) 2002-10-29 2011-07-27 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
JP2006516094A (ja) 2002-11-08 2006-06-22 ジェネンテック・インコーポレーテッド ナチュラルキラー細胞関連疾患の治療のための組成物と方法
EP2314676A1 (en) 2002-11-26 2011-04-27 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
SI1575517T1 (sl) 2002-12-24 2012-06-29 Rinat Neuroscience Corp Protitelesa proti ĺ˝iväśnemu rastnemu dejavniku in metode njihove uporabe
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
EP2526960A1 (en) 2003-03-12 2012-11-28 Genentech, Inc. Use of BV8 and/or EG-VEGF to promote hematopoiesis
EP1608967A4 (en) 2003-04-01 2006-08-09 Genentech Inc COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF TUMORS
KR20120104408A (ko) 2003-05-30 2012-09-20 제넨테크, 인크. 항-ｖｅｇｆ 항체를 사용한 치료
ES2537738T3 (es) 2003-06-05 2015-06-11 Genentech, Inc. Terapia de combinación para trastornos de células B
ATE465275T1 (de) 2003-06-13 2010-05-15 Univ Pittsburgh Überwachung von immunologischen, hämatologischen und entzündlichen erkrankungen
MX341074B (es) 2003-07-08 2016-08-05 Genentech Inc Polipeptidos heterologos il-17 a/f y usos terapeuticos de los mismos.
EP1648940B1 (en) 2003-07-28 2016-04-27 Genentech, Inc. Reducing protein a leaching during protein a affinity chromatography
JP4643450B2 (ja) 2003-08-08 2011-03-02 株式会社ペルセウスプロテオミクス 癌高発現遺伝子
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
SI2295073T1 (sl) 2003-11-17 2014-07-31 Genentech, Inc. Protitelo proti CD22 za zdravljenje tumorja hematopoetskega izvora
US7750123B2 (en) 2003-11-25 2010-07-06 Dana Farber Cancer Institute, Inc. Antibodies against SARS-CoV and methods of use thereof
US7312320B2 (en) 2003-12-10 2007-12-25 Novimmune Sa Neutralizing antibodies and methods of use thereof
AU2004298483A1 (en) 2003-12-11 2005-06-30 Genentech, Inc. Methods and compositions for inhibiting c-met dimerization and activation
BRPI0417270A (pt) 2003-12-23 2007-03-27 Rinat Neuroscience Corp anticorpos agonistas antitrkc e métodos para utilização dos mesmos
ES2337473T3 (es) 2004-02-19 2010-04-26 Genentech, Inc. Anticuerpos reparadores con cdr.
WO2006074418A2 (en) 2005-01-07 2006-07-13 Diadexus, Inc. Ovr110 antibody compositions and methods of use
CN102512675A (zh) 2004-06-04 2012-06-27 健泰科生物技术公司 用于治疗多发性硬化的方法
SI1771474T1 (sl) 2004-07-20 2010-06-30 Genentech Inc Inhibitorji angiopoetinu podobnega proteina kombinacije in njihova uporaba
JP5042828B2 (ja) 2004-07-30 2012-10-03 ライナット ニューロサイエンス コーポレイション アミロイド−ベータ・ペプチドに対して向けられる抗体、および該抗体を用いる方法
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US7449184B2 (en) 2005-01-21 2008-11-11 Genentech, Inc. Fixed dosing of HER antibodies
WO2006089133A2 (en) 2005-02-15 2006-08-24 Duke University Anti-cd19 antibodies and uses in oncology
EP1850874B1 (en) 2005-02-23 2013-10-16 Genentech, Inc. Extending time to disease progression or survival in ovarian cancer patients using pertuzumab
ATE526412T1 (de) 2005-04-11 2011-10-15 Ca Nat Research Council Identifizierung einer beta-1,3-n- acetylgalactosaminyltransferase (cgte) aus campylobacter jejuni lio87
DE602006018458D1 (de) 2005-04-29 2011-01-05 Univ California Antikörper gegen histonmodifikationen für die klinische krebsdiagnose und -prognose
JO3058B1 (ar) 2005-04-29 2017-03-15 Applied Molecular Evolution Inc الاجسام المضادة لمضادات -اي ال-6,تركيباتها طرقها واستعمالاتها
CA2607281C (en) 2005-05-05 2023-10-03 Duke University Anti-cd19 antibody therapy for autoimmune disease
PL3263581T3 (pl) 2005-05-17 2021-05-04 University Of Connecticut Kompozycje i sposoby immunomodulacji w organizmie
CN101252951B (zh) 2005-06-30 2011-12-21 森托科尔公司 抗il-23抗体、组合物、方法和用途
WO2007021841A2 (en) 2005-08-10 2007-02-22 Macrogenics, Inc. Identification and engineering of antibodies with variant fc regions and methods of using same
BRPI0618705B8 (pt) 2005-11-14 2021-05-25 Labrys Biologics Inc anticorpos antagonistas humanizados direcionados contra peptídeo relacionado ao gene da calcitonina, composição farmacêutica e uso dos mesmos
WO2007065027A2 (en) 2005-12-02 2007-06-07 Dana Farber Cancer Institute Carbonic anhydrase ix (g250) antibodies and methods of use thereof
RU2426742C2 (ru) 2005-12-02 2011-08-20 Дженентек, Инк. Составы и способы лечения заболеваний и нарушений, связанных с передачей сигналов цитокинами
EP3309170B1 (en) 2005-12-15 2019-05-22 Genentech, Inc. Polyubiquitin antibodies
EP1971366B1 (en) 2005-12-29 2014-07-30 Janssen Biotech, Inc. Human anti-il-23 antibodies, compositions, methods and uses
KR101589391B1 (ko) 2006-01-05 2016-01-29 제넨테크, 인크. 항-ｅｐｈｂ４ 항체 및 그의 사용 방법
WO2007092431A2 (en) 2006-02-06 2007-08-16 Rhode Island Hospital Gpr30 estrogen receptor in breast cancers
ZA200807714B (en) 2006-02-17 2010-01-27 Genentech Inc Gene disruptions, compositions and methods relating thereto
EP2650306A1 (en) 2006-03-06 2013-10-16 Aeres Biomedical Limited Humanized Anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
HUE025989T2 (hu) 2006-03-21 2016-05-30 Genentech Inc Alfa5béta1-antagonistákat magában foglaló kombinációs terápia
US20100278821A1 (en) 2006-03-21 2010-11-04 The Regents Of The University Of California N-cadherin: target for cancer diagnosis and therapy
WO2007109347A2 (en) 2006-03-21 2007-09-27 The Regents Of The University Of California N-cadherin and ly6 e: targets for cancer diagnosis and therapy
CA2647107A1 (en) 2006-03-23 2007-09-27 Novartis Ag Anti-tumor cell antigen antibody therapeutics
CA2647277A1 (en) 2006-04-05 2007-11-08 Genentech, Inc. Method for using boc/cdo to modulate hedgehog signaling
AU2007247969A1 (en) 2006-05-04 2007-11-15 Genentech, Inc. Methods and compositions relating to ZPA polypeptides
EP2447282B1 (en) 2006-05-30 2016-01-27 Genentech, Inc. Anti-CD22 Antibodies, their Immunoconjugates and uses thereof
EP2024391A2 (en) 2006-06-01 2009-02-18 Genentech, Inc. Crystal structure of crig and c3b: crig complex
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
EP2471809B1 (en) 2006-07-11 2015-09-02 University Of Medicine And Dentistry Of New Jersey Proteins, nucleic acids encoding the same and associated methods of use
WO2008011081A2 (en) 2006-07-19 2008-01-24 The Trustees Of The University Of Pennsylvania Wsx-1/p28 as a target for anti-inflammatory responses
EP2057465A4 (en) 2006-08-09 2010-04-21 Homestead Clinical Corp SPECIFIC ORGAN PROTEINS AND METHODS OF USE
CN104059149B (zh) 2006-08-22 2017-04-12 诺沃诺蒂斯克股份有限公司 具有改进性能的抗‑C5aR抗体
WO2008023840A2 (en) 2006-08-25 2008-02-28 Oncotherapy Science, Inc. Prognostic markers and therapeutic targets for lung cancer
CN101557818A (zh) 2006-10-03 2009-10-14 新泽西医科和牙科大学 Atap肽、编码atap肽的核酸以及相关的应用方法
PL2845866T3 (pl) 2006-10-27 2017-10-31 Genentech Inc Przeciwciała i immunokoniugaty oraz ich zastosowanie
CA2670320A1 (en) 2006-11-21 2008-11-20 The Regents Of The University Of California Modulation of rhamm (cd168) for selective adipose tissue development
JP5391073B2 (ja) 2006-11-27 2014-01-15 ディアデクサス インコーポレーテッド Ｏｖｒ１１０抗体組成物および使用方法
AU2008218199B2 (en) 2007-02-22 2013-10-31 Genentech, Inc. Methods for detecting inflammatory bowel disease
CN103432580A (zh) 2007-03-02 2013-12-11 健泰科生物技术公司 基于低her3表达预测对her二聚化抑制剂的响应
US20080279851A1 (en) 2007-05-07 2008-11-13 Medlmmune, Llc Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease
CN101720232B (zh) 2007-05-14 2013-07-10 诺维莫尼公司 具有修饰的效应器功能的fc受体结合型多肽
WO2008154249A2 (en) 2007-06-08 2008-12-18 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
MX2009012924A (es) 2007-06-08 2010-03-25 Australian Poultry Crc Pty Ltd Toxina clostridial netb.
US20090053786A1 (en) 2007-07-09 2009-02-26 Yung-Hsiang Kao Prevention of disulfide bond reduction during recombinant production of polypeptides
CR20190516A (es) 2007-07-16 2020-02-18 Genentech Inc ANTICUERPOS ANTI-CD79B E INMUNOCONJUGADOS (Divisional 2015-0040)
PE20090481A1 (es) 2007-07-16 2009-05-18 Genentech Inc Anticuerpos anti-cd79b e inmunoconjugados humanizados y metodos de uso
MX2010001307A (es) 2007-08-02 2010-07-30 Novimmune Sa Anticuerpos anti-proteína regulada con la activación, expresada y secretada por los linfocitos t normales y metodos de uso de los mismos.
EP2207805B1 (en) 2007-10-02 2014-07-09 Genentech, Inc. Nlrr-1 antagonists and uses thereof
ES2662845T3 (es) 2007-11-07 2018-04-10 Genentech, Inc. IL-22 para su uso en el tratamiento de trastornos microbianos
CA2706729A1 (en) 2007-11-29 2009-06-11 Genentech, Inc. Gene expression markers for inflammatory bowel disease
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
CN101969971A (zh) 2007-11-30 2011-02-09 雅培制药有限公司 蛋白制剂及其制备方法
AR069501A1 (es) 2007-11-30 2010-01-27 Genentech Inc Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
CN101970483A (zh) 2007-12-06 2011-02-09 达纳-法伯癌症研究公司 抗流感病毒抗体及其使用方法
KR20130087632A (ko) 2007-12-17 2013-08-06 화이자 리미티드 간질성 방광염의 치료
NZ585959A (en) 2007-12-18 2012-09-28 Bioalliance Cv Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
WO2009091547A1 (en) 2008-01-15 2009-07-23 The Board Of Trustees Of The Leland Stanford Junior University Markers of acute myeloid leukemia stem cells
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
CN101981055B (zh) 2008-01-31 2016-03-09 健泰科生物技术公司 抗cd79b抗体和免疫偶联物及使用方法
MX364200B (es) 2008-04-09 2019-04-16 Genentech Inc Composiciones y metodos novedosos para el tratamiento de las enfermedades relacionadas con la inmunidad.
WO2009140684A2 (en) 2008-05-16 2009-11-19 Genentech, Inc. Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7integrin antagonists
EP2283862B1 (en) 2008-06-02 2018-08-08 The University of Tokyo Combination treatment of cancer comprising anti-mfg-e8 antibody
WO2009150623A1 (en) 2008-06-13 2009-12-17 Pfizer Inc Treatment of chronic prostatitis
CA2736799A1 (en) 2008-08-25 2010-03-11 Burnham Institute For Medical Research Conserved hemagglutinin epitope, antibodies to the epitope, and methods of use
US8790642B2 (en) 2008-08-29 2014-07-29 Genentech, Inc. Cross-reactive and bispecific anti-IL-17A/F antibodies
KR20110051245A (ko) 2008-09-10 2011-05-17 제넨테크, 인크. 안구 혈관신생의 억제 방법
TWI445716B (zh) 2008-09-12 2014-07-21 Rinat Neuroscience Corp Ｐｃｓｋ９拮抗劑類
TW201014605A (en) 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
US8192738B2 (en) 2008-09-19 2012-06-05 Medimmune, Llc Targeted antibodies directed to DLL4
PE20110707A1 (es) 2008-10-14 2011-10-11 Genentech Inc Variantes de inmunoglobulinas
BRPI0921845A2 (pt) 2008-11-12 2019-09-17 Medimmune Llc formulação aquosa estéril estável, forma de dosagem unitária farmacêutica, seringa pré-carregada, e, métodos para tratar uma doença ou distúrbio, para tratar ou prevenir rejeição, para esgotar células t que expressam icos em um paciente humano, e para interromper arquitetura central germinal em um órgão linfóide secundário de um primata
SG171764A1 (en) 2008-12-16 2011-07-28 Millipore Corp Purification of proteins
AU2009335788A1 (en) 2008-12-17 2011-07-07 Genentech, Inc. Hepatitis C virus combination therapy
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
EP3318573A1 (en) 2008-12-23 2018-05-09 F. Hoffmann-La Roche AG Mmunoglobulin variants with altered binding to protein a
US20120114667A1 (en) 2008-12-23 2012-05-10 Medimmune Limited TARGETED BINDING AGENTS DIRECTED TO a5BETA1 AND USES THEREOF
WO2010086828A2 (en) 2009-02-02 2010-08-05 Rinat Neuroscience Corporation Agonist anti-trkb monoclonal antibodies
SI3260136T1 (sl) 2009-03-17 2021-05-31 Theraclone Sciences, Inc. Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
SG174904A1 (en) 2009-03-25 2011-11-28 Genentech Inc Anti-fgfr3 antibodies and methods using same
CA2757382A1 (en) 2009-04-01 2010-10-21 Kristi Elkins Anti-fcrh5 antibodies and immunoconjugates
RU2605318C2 (ru) 2009-05-05 2016-12-20 Новиммун С.А. Анти-il-17f антитела и способы их применения
WO2010146511A1 (en) 2009-06-17 2010-12-23 Pfizer Limited Treatment of overactive bladder
WO2011005715A1 (en) 2009-07-07 2011-01-13 Genentech, Inc. Diagnosis and treatment of autoimmune demyelinating diseases
WO2011011339A1 (en) 2009-07-20 2011-01-27 Genentech, Inc. Gene expression markers for crohn's disease
TW201106972A (en) 2009-07-27 2011-03-01 Genentech Inc Combination treatments
NZ597809A (en) 2009-08-06 2014-05-30 Genentech Inc Method to improve virus removal in protein purification
US20110039300A1 (en) 2009-08-10 2011-02-17 Robert Bayer Antibodies with enhanced adcc functions
WO2011019679A1 (en) 2009-08-11 2011-02-17 Allergan, Inc. Ccr2 inhibitors for treating conditions of the eye
LT2464725T (lt) 2009-08-11 2020-06-10 F. Hoffmann-La Roche Ag Baltymų gamyba ląstelių mitybinėje terpėje, kurioje nėra glutamino
WO2011019622A1 (en) 2009-08-14 2011-02-17 Genentech, Inc. Cell culture methods to make antibodies with enhanced adcc function
WO2011028753A1 (en) 2009-09-01 2011-03-10 Genentech, Inc. Enhanced protein purification through a modified protein a elution
US9321823B2 (en) 2009-09-02 2016-04-26 Genentech, Inc. Mutant smoothened and methods of using the same
AU2010303415B2 (en) 2009-10-07 2015-02-19 Macrogenics, Inc. Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
EP2488640B1 (en) 2009-10-14 2018-09-26 Nanyang Technological University Antiproliferative agent
AR078716A1 (es) 2009-10-22 2011-11-30 Genentech Inc Anticuerpos antihepsina y metodos para su uso
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
WO2011056494A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
SI2496601T1 (sl) 2009-11-05 2017-09-29 F. Hoffmann-La Roche Ag Tehnike in sestavek za sekrecijo heterolognih polipeptidov
RU2012124093A (ru) 2009-11-12 2013-12-20 Дженентек, Инк. Способ увеличения плотности дендритных шипиков
CA2781290A1 (en) 2009-11-20 2011-05-26 Lynn K. Gordon Epithelial membrane protein-2 (emp2) and proliferative vitreoretinopathy (pvr)
MX359551B (es) 2009-11-24 2018-10-02 Medimmune Ltd Agentes de union diana contra b7-h1.
EP3002297B1 (en) 2009-11-30 2020-04-08 F. Hoffmann-La Roche AG Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211)
ES2565208T3 (es) 2009-12-11 2016-04-01 F. Hoffmann-La Roche Ag Anticuerpos anti-VEGF-C y métodos de uso de los mismos
RU2609658C2 (ru) 2009-12-21 2017-02-02 Дженентек, Инк. Состав, содержащий антитело
WO2011080796A1 (en) 2009-12-28 2011-07-07 Oncotherapy Science, Inc. Anti-cdh3 antibodies and uses thereof
WO2011082187A1 (en) 2009-12-30 2011-07-07 Genentech, Inc. Methods for modulating a pdgf-aa mediated biological response
WO2011094759A2 (en) 2010-02-01 2011-08-04 The Regents Of The University Of California Novel diagnostic and therapeutic targets associated with or regulated by n-cadherin expression and/or epithelial to mesenchymal transition (emt) in prostate cancer and other malignancies
WO2011100403A1 (en) 2010-02-10 2011-08-18 Immunogen, Inc Cd20 antibodies and uses thereof
EP4219560A3 (en) 2010-02-18 2023-08-23 The Regents of The University of California Integrin alpha v beta 8 neutralizing antibody
AR080243A1 (es) 2010-02-23 2012-03-21 Genentech Inc Composiciones y metodos para el diagnostico y tratamiento de tumores
AR080291A1 (es) 2010-02-24 2012-03-28 Rinat Neuroscience Corp Anticuerpos antagonistas anti receptor de il-7 y procedimientos
KR20120138241A (ko) 2010-03-11 2012-12-24 화이자 인코포레이티드 ｐＨ 의존성 항원 결합을 갖는 항체
HUE036157T2 (hu) 2010-03-30 2018-06-28 Janssen Biotech Inc Humanizált IL-25 ellenanyagok
BR112012027828A2 (pt) 2010-05-03 2016-08-09 Genentech Inc composição de matéria, artigo de fabricação e método de redução da viscosidade de uma formulação contendo proteína e de preparação de uma formulação aquosa contendo proteína
KR20130079384A (ko) 2010-05-03 2013-07-10 제넨테크, 인크. 종양의 진단 및 치료를 위한 조성물 및 방법
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
PL2575847T5 (pl) 2010-05-25 2022-07-18 F.Hoffmann-La Roche Ag Sposoby oczyszczania polipeptydów
EP2576580B1 (en) 2010-05-28 2016-09-14 F.Hoffmann-La Roche Ag Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase
ES2648885T3 (es) 2010-06-02 2018-01-08 Dana-Farber Cancer Institute, Inc. Anticuerpos monoclonales humanizados y métodos de uso
US20110311527A1 (en) 2010-06-16 2011-12-22 Allergan, Inc. IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS
NZ603581A (en) 2010-06-19 2015-05-29 Sloan Kettering Inst Cancer Anti-gd2 antibodies
WO2012019061A2 (en) 2010-08-05 2012-02-09 Stem Centrx, Inc. Novel effectors and methods of use
CN103154032A (zh) 2010-08-13 2013-06-12 弗·哈夫曼-拉罗切有限公司 用于疾病治疗的针对IL-1β和IL-18的抗体
CA2809369A1 (en) 2010-08-27 2012-03-01 Stem Centrx, Inc. Notum protein modulators and methods of use
ES2774369T3 (es) 2010-08-31 2020-07-20 Theraclone Science Int Anticuerpo de neutralización del virus de la inmunodeficiencia humana
EP2611464B1 (en) 2010-09-03 2018-04-25 AbbVie Stemcentrx LLC Novel modulators and methods of use
WO2012030512A1 (en) 2010-09-03 2012-03-08 Percivia Llc. Flow-through protein purification process
CA2813738A1 (en) 2010-10-05 2012-04-12 Genentech, Inc. Mutant smoothened and methods of using the same
DK2635607T3 (da) 2010-11-05 2019-11-18 Zymeworks Inc Stabilt heterodimert antistofdesign med mutationer i fc-domænet
WO2012099566A1 (en) 2010-11-17 2012-07-26 Sea Lane Biotechnologies, Llc Influenza virus neutralizing agents that mimic the binding site of an influenza neutralizing antibody
WO2012071436A1 (en) 2010-11-24 2012-05-31 Genentech, Inc. Method of treating autoimmune inflammatory disorders using il-23r loss-of-function mutants
EP2648749A2 (en) 2010-12-08 2013-10-16 Stem Centrx, Inc. Novel modulators and methods of use
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
SA112330278B1 (ar) 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
CN103533929A (zh) 2011-03-15 2014-01-22 特罗科隆科学有限公司 用于流行性感冒的治疗和诊断的组合物和方法
MX2013011130A (es) 2011-03-31 2013-10-30 Genentech Inc Metodos de administracion de antagonistas de integrina beta7.
AU2012239997A1 (en) 2011-04-07 2013-10-17 Amgen Inc. Novel EGFR binding proteins
CA2837169C (en) 2011-05-24 2021-11-09 Zyngenia, Inc. Multispecific complexes comprising angiopoietin-2-binding peptide and their uses
EP2734546A1 (en) 2011-07-18 2014-05-28 Amgen Inc. Apelin antigen-binding proteins and uses thereof
BR112014010406A2 (pt) 2011-11-02 2017-04-25 Genentech Inc cromatografia de sobrecarga e eluto
HRP20211773T1 (hr) 2011-11-04 2022-03-04 Zymeworks Inc. Stabilna heterodimerni dizajn antitijela s mutacijama u fc domeni
EP2776470A2 (en) 2011-11-11 2014-09-17 Rinat Neuroscience Corporation Antibodies specific for trop-2 and their uses
WO2013093693A1 (en) 2011-12-22 2013-06-27 Rinat Neuroscience Corp. Staphylococcus aureus specific antibodies and uses thereof
AU2012356206A1 (en) 2011-12-22 2014-06-26 Rinat Neuroscience Corp. Human growth hormone receptor antagonist antibodies and methods of use thereof
EP2793941A1 (en) 2011-12-23 2014-10-29 F.Hoffmann-La Roche Ag Articles of manufacture and methods for co-administration of antibodies
WO2013101771A2 (en) 2011-12-30 2013-07-04 Genentech, Inc. Compositions and method for treating autoimmune diseases
AU2013208007A1 (en) 2012-01-09 2014-07-31 The Scripps Research Institute Humanized antibodies with ultralong CDR3
CA2863224A1 (en) 2012-01-09 2013-07-18 The Scripps Research Institute Ultralong complementarity determining regions and uses thereof
KR102338833B1 (ko) 2012-02-06 2021-12-13 인히브릭스, 인크. Cd47 항체 및 그 사용 방법
WO2013126746A2 (en) 2012-02-24 2013-08-29 Stem Centrx, Inc. Novel modulators and methods of use
AU2013237929B2 (en) 2012-03-29 2017-09-14 Novimmune S.A. Anti-TLR4 antibodies and uses thereof
CA2871751C (en) 2012-05-04 2021-08-24 Dana-Farber Cancer Institute, Inc. Affinity matured anti-ccr4 humanized monoclonal antibodies and methods of use
WO2013166594A1 (en) 2012-05-10 2013-11-14 Zymeworks Inc. Heteromultimer constructs of immunoglobulin heavy chains with mutations in the fc domain
BR112014031028A2 (pt) 2012-06-11 2017-08-15 Amgen Inc Proteína de ligação ao antígeno isolado, ácido nucléico isolado, vetor de expressão, célula hospedeira, método para produzir uma proteína de ligação ao antígeno, composição, método para reduzir ou bloquear a atividade de miostatina, activin a ou gdf-11, método para aumentar a firmeza da massa muscular ou aumentar a proporção da firmeza da massa muscular para massa adiposo em um indivíduo necessitado do referido tratamento, método para tratar ou prevenir uma doença prejudicial do músculo em um indivíduo sofrendo do referido distúrbio e anticorpo receptor duplo antagonista
US20150175979A1 (en) 2012-07-23 2015-06-25 La Jolla Institute For Allergy And Immunology Ptprs and proteoglycans in autoimmune disease
IN2015MN00139A (ja) 2012-09-25 2015-10-16 Glenmark Pharmaceuticals Sa
CN107892719B (zh) 2012-10-04 2022-01-14 达纳－法伯癌症研究所公司 人单克隆抗-pd-l1抗体和使用方法
MX2015005874A (es) 2012-11-09 2015-09-10 Pfizer Anticuerpos especificos del factor de crecimiento b derivados de plaquetas y composiciones y usos de estos.
CA2892585C (en) 2012-12-03 2022-07-05 Novimmune S.A. Anti-cd47 antibodies and methods of use thereof
BR112015018851A2 (pt) 2013-02-06 2017-07-18 Inhibrx Llc anticorpos cd47 de não depleção de plaquetas e de não depleção de células vermelhas do sangue, e métodos de uso dos mesmos
ME03394B (me) 2013-02-22 2020-01-20 Medimmune Ltd Antidllз-antitelo-pbd konjugati i nihovа upotreba
SI2968467T1 (sl) 2013-03-13 2020-11-30 F. Hoffmann-La Roche Ag Pripravki z zmanjšano oksidacijo
BR112015022210A8 (pt) 2013-03-13 2018-01-23 Genentech Inc formulações de anticorpo
SG10201705525VA (en) 2013-03-13 2017-08-30 Genentech Inc Formulations with reduced oxidation
SG11201507359SA (en) 2013-03-15 2015-10-29 Dana Farber Cancer Inst Inc Flavivirus neutralizing antibodies and methods of use thereof
CA2903596C (en) 2013-03-15 2023-10-03 Genentech, Inc. Cell culture compositions with antioxidants and methods for polypeptide production
BR112015023752B1 (pt) 2013-03-15 2023-11-14 Zyngenia, Inc. Domínio de reconhecimento modular (mrd), complexo compreendendo mrd e cetuximabe, usos do complexo para inibir a angiogênese e tratar câncer e composição farmacêutica compreendendo o dito complexo
US10167341B2 (en) 2013-03-15 2019-01-01 Memorial Sloan Kettering Cancer Center High affinity anti-GD2 antibodies
US9447193B2 (en) 2013-03-24 2016-09-20 Development Center For Biotechnology Methods for suppressing cancer by inhibition of TMCC3
CN105143876B (zh) 2013-03-27 2018-04-20 豪夫迈·罗氏有限公司 生物标志物用于评估用β7整联蛋白拮抗剂治疗胃肠炎性病症的用途
WO2014172661A1 (en) 2013-04-19 2014-10-23 The Regent Of The University Of California Lone star virus
MX2015015339A (es) 2013-05-07 2016-07-15 Rinat Neuroscience Corp Anticuerpos de receptor anti-glucagon y metodos de uso de los mismos.
WO2015006686A1 (en) 2013-07-12 2015-01-15 Genentech, Inc. Elucidation of ion exchange chromatography input optimization
JP6636920B2 (ja) 2013-07-16 2020-01-29 ジェネンテック， インコーポレイテッド Ｐｄ−１軸結合アンタゴニスト及びｔｉｇｉｔ阻害剤を使用するがんの治療方法
EP3022224A2 (en) 2013-07-18 2016-05-25 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
CN105814074B (zh) 2013-07-18 2020-04-21 图鲁斯生物科学有限责任公司 具有超长互补决定区的人源化抗体
KR20180021234A (ko) 2013-08-12 2018-02-28 제넨테크, 인크. 보체-연관 상태의 치료를 위한 조성물 및 방법
WO2015023851A1 (en) 2013-08-14 2015-02-19 The Governing Council Of The University Of Toronto Antibodies against frizzled proteins and methods of use thereof
SG11201601416VA (en) 2013-08-28 2016-03-30 Stemcentrx Inc Novel sez6 modulators and methods of use
AU2014312215B2 (en) 2013-08-28 2020-02-27 Abbvie Stemcentrx Llc Site-specific antibody conjugation methods and compositions
JP6736464B2 (ja) 2013-08-29 2020-08-05 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ 細胞透過性コンジュゲート及びその使用の方法
PT3049441T (pt) 2013-09-27 2020-01-21 Hoffmann La Roche Formulações de anticorpos anti-pdl1
AU2014343636A1 (en) 2013-11-04 2016-06-02 Glenmark Pharmaceuticals S.A. Production of T cell retargeting hetero-dimeric immunoglobulins
CA3056647A1 (en) 2013-11-13 2015-05-21 Robert ARCH Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof
WO2015084625A1 (en) 2013-12-02 2015-06-11 Baylor College Of Medicine Identification of a new polypeptide hormone for maintenance of optimal body weight and blood glucose
WO2015087187A1 (en) 2013-12-10 2015-06-18 Rinat Neuroscience Corp. Anti-sclerostin antibodies
WO2015095410A1 (en) 2013-12-17 2015-06-25 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
KR102447878B1 (ko) 2013-12-17 2022-09-26 제넨테크, 인크. Pd-1 축 결합 길항제 및 탁산을 이용한 암 치료 방법
WO2015095423A2 (en) 2013-12-17 2015-06-25 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
DK3087098T3 (da) 2013-12-24 2020-06-08 Janssen Pharmaceutica Nv Anti-Vista-antistoffer og -fragmenter
WO2016114819A1 (en) 2015-01-16 2016-07-21 Academia Sinica Compositions and methods for treatment and detection of cancers
JP2017507118A (ja) 2014-01-16 2017-03-16 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ がんの処置および検出のための組成物および方法
WO2015109212A1 (en) 2014-01-17 2015-07-23 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof
JP6736467B2 (ja) 2014-02-04 2020-08-05 ジェネンテック， インコーポレイテッド 平滑化変異体及びその使用方法
WO2015143194A2 (en) 2014-03-19 2015-09-24 Dana-Farber Cancer Institute, Inc. Immunogenetic restriction on elicitation of antibodies
RS65360B1 (sr) 2014-03-21 2024-04-30 Teva Pharmaceuticals Int Gmbh Antagonistička antitela specifična za peptid genski srodan kalcitoninu i postupci njihove upotrebe
MA39804A (fr) 2014-03-27 2017-02-01 Hoffmann La Roche Méthodes permettant le diagnostic et le traitement d'une maladie inflammatoire de l'intestin
EP3131917B1 (en) 2014-04-18 2020-06-17 The Board of Trustees of the Leland Stanford Junior University Humanized and chimeric monoclonal antibodies to cd99
PT3148581T (pt) 2014-05-30 2020-01-06 Henlix Biotech Co Ltd Anticorpos antirrecetor do fator de crescimento epidérmico (egfr)
ES2779412T3 (es) 2014-06-17 2020-08-17 Medimmune Ltd Anticuerpos Alfa-V Beta-8 mejorados
TWI695011B (zh) 2014-06-18 2020-06-01 美商梅爾莎納醫療公司 抗ｈｅｒ２表位之單株抗體及其使用之方法
RU2017115315A (ru) 2014-10-03 2018-11-08 Дана-Фарбер Кэнсер Инститьют, Инк. Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения
WO2016057488A1 (en) 2014-10-06 2016-04-14 Dana-Farber Cancer Institute, Inc. Humanized cc chemokine receptor 4 (ccr4) antibodies and methods of use thereof
EP3753948A1 (en) 2014-11-05 2020-12-23 Genentech, Inc. Methods of producing two chain proteins in bacteria
CA2966558C (en) 2014-11-05 2024-03-12 Genentech, Inc. Methods of producing two chain proteins in bacteria
CN106999583A (zh) 2014-11-17 2017-08-01 豪夫迈·罗氏有限公司 包含ox40结合激动剂和pd‑1轴结合拮抗剂的组合疗法
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
WO2016115275A1 (en) 2015-01-13 2016-07-21 City Of Hope Ctla4-binding protein peptide-linker masks
EP3795168A1 (en) 2015-01-16 2021-03-24 City of Hope Cell penetrating antibodies
EP3248013B1 (en) 2015-01-24 2020-07-15 Academia Sinica Cancer markers and methods of use thereof
EP3253784B1 (en) 2015-02-04 2020-05-06 Genentech, Inc. Mutant smoothened and methods of using the same
KR20170120601A (ko) 2015-02-26 2017-10-31 제넨테크, 인크. 인테그린 베타7 길항제 및 크론병을 치료하는 방법
MX2017012352A (es) 2015-04-03 2018-01-26 Eureka Therapeutics Inc Construccion dirigida a complejos de peptido de alfa-fetoproteina/complejo principal de histocompatibilidad (afp/cph) y usos de los mismos.
US11135282B2 (en) 2015-04-08 2021-10-05 Dana-Farber Cancer Institute, Inc. Humanized influenza monoclonal antibodies and methods of use thereof
SG10201912823PA (en) 2015-04-13 2020-02-27 Pfizer Therapeutic antibodies and their uses
JP6956639B2 (ja) 2015-05-01 2021-11-02 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 抗ｃｃｒ４抗体を用いてサイトカイン発現を媒介する方法
EP3294764B1 (en) 2015-05-15 2020-12-30 City of Hope Chimeric antigen receptor compositions
HRP20231392T1 (hr) 2015-05-15 2024-04-26 The General Hospital Corporation Antagonistička protutijela na superobitelj receptora za faktor tumorske nekroze
EP3303619B1 (en) 2015-05-29 2020-06-10 H. Hoffnabb-La Roche Ag Pd-l1 promoter methylation in cancer
JP2018516933A (ja) 2015-06-02 2018-06-28 ジェネンテック， インコーポレイテッド 抗ｉｌ−３４抗体を使用して神経学的疾患を治療するための組成物及び方法
CN107771076A (zh) 2015-06-17 2018-03-06 豪夫迈·罗氏有限公司 使用pd‑1轴结合拮抗剂和紫杉烷治疗局部晚期或转移性乳腺癌的方法
CA2990360C (en) 2015-06-24 2024-02-13 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments
US11066481B2 (en) 2015-07-23 2021-07-20 The Regents Of The University Of California Antibodies to coagulation factor XIa and uses thereof
US11661463B2 (en) 2015-08-06 2023-05-30 City Of Hope Cell penetrating protein-antibody conjugates and methods of use
EP4223784A3 (en) 2015-09-02 2023-10-04 The Regents of the University of Colorado, a body corporate Compositions and methods for modulating t-cell mediated immune response
WO2017062682A2 (en) 2015-10-06 2017-04-13 Genentech, Inc. Method for treating multiple sclerosis
WO2017070561A1 (en) 2015-10-23 2017-04-27 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof
CN112274649A (zh) 2015-12-10 2021-01-29 希望之城 细胞穿透花青偶联抗体
AU2016379425B2 (en) 2015-12-24 2021-11-11 Corvus Pharmaceuticals, Inc. Methods of treating cancer
SG11201804951SA (en) 2015-12-30 2018-07-30 Genentech Inc Use of tryptophan derivatives for protein formulations
IL299759A (en) 2015-12-30 2023-03-01 Genentech Inc Formulations with reduced polysorbate dissolution
MX2018008347A (es) 2016-01-08 2018-12-06 Hoffmann La Roche Metodos de tratamiento de canceres positivos para ace utilizando antagonistas de union a eje pd-1 y anticuerpos biespecificos anti-ace/anti-cd3.
JP2019506398A (ja) 2016-01-21 2019-03-07 ファイザー・インク 上皮増殖因子受容体変異体ｉｉｉおよびｃｄ３の単一および二重特異性抗体およびそれらの使用
US11513127B2 (en) 2016-01-25 2022-11-29 Genentech, Inc. Methods for assaying T-cell dependent bispecific antibodies
JP2019509721A (ja) 2016-02-04 2019-04-11 キュリス，インコーポレイテッド 突然変異体スムースンド及びその使用方法
WO2017137830A1 (en) 2016-02-12 2017-08-17 Janssen Pharmaceutica Nv Anti-vista (b7h5) antibodies
EA201892190A1 (ru) 2016-03-29 2019-04-30 Янссен Байотек, Инк. Лечение псориаза антителом к ил-12 и/или ил-23 с возрастанием интервала между введениями дозы
WO2017173302A2 (en) 2016-04-01 2017-10-05 The Regents Of The University Of California Inhibitors of integrin alpha 5 beta 1 and methods of use
WO2017175058A1 (en) 2016-04-07 2017-10-12 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
AU2017264754A1 (en) 2016-05-10 2018-12-13 Genentech, Inc. Methods of decreasing trisulfide bonds during recombinant production of polypeptides
MX2018015173A (es) 2016-06-17 2019-07-04 Genentech Inc Purificacion de anticuerpos multiespecificos.
CN109689689B (zh) 2016-07-22 2022-12-06 丹娜法伯癌症研究所公司 糖皮质激素诱导肿瘤坏死因子受体(gitr)抗体及其使用方法
CN106079858B (zh) * 2016-08-03 2017-05-17 钟晴晴 一种丝网印刷机
EP3494139B1 (en) 2016-08-05 2022-01-12 F. Hoffmann-La Roche AG Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
JP7250674B2 (ja) 2016-08-08 2023-04-03 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト がんの治療及び診断方法
MX2019001572A (es) 2016-08-15 2019-08-29 Genentech Inc Método de cromatografía para cuantificar un tensioactivo no iónico en una composición que comprende el tensioactivo no iónico y un polipéptido.
EP3507305A1 (en) 2016-09-02 2019-07-10 Dana-Farber Cancer Institute, Inc. Composition and methods of treating b cell disorders
US20190233505A1 (en) 2016-09-06 2019-08-01 Dana-Farber Cancer Institute, Inc. Methods of treating or preventing zika virus infection
TW201825674A (zh) 2016-09-09 2018-07-16 美商艾斯合顧問有限公司 表現雙特異性接合分子的溶瘤病毒
EP4339615A3 (en) 2016-09-16 2024-05-22 Shanghai Henlius Biotech, Inc. Anti-pd-1 antibodies
EA201990548A1 (ru) 2016-09-23 2019-09-30 Тева Фармасьютикалз Интернэшнл Гмбх Лечение кластерной головной боли
MX2019003337A (es) 2016-09-23 2019-09-26 Teva Pharmaceuticals Int Gmbh Tratamiento para migraña refractaria.
CN109862913B (zh) 2016-09-29 2023-09-05 加利福尼亚大学董事会 用于免疫疗法的αvβ8整联蛋白复合物的中和抗体
JP2020500152A (ja) 2016-09-30 2020-01-09 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ２３特異的抗体で乾癬を治療する安全かつ有効な方法
AU2017353936A1 (en) 2016-11-04 2019-05-02 Novimmune Sa Anti-CD19 antibodies and methods of use thereof
WO2018089967A1 (en) 2016-11-14 2018-05-17 Virginia Commonwealth University Inhibitors of cancer invasion, attachment, and/or metastasis
EP3541422A4 (en) 2016-11-16 2020-05-06 Janssen Biotech, Inc. METHOD FOR TREATING PSORIASIS WITH A SPECIFIC ANTI-IL-23 ANTIBODY
TW201825515A (zh) 2017-01-04 2018-07-16 美商伊繆諾金公司 Ｍｅｔ抗體以及其免疫結合物及用途
WO2018152496A1 (en) 2017-02-17 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Compositions and methods for the diagnosis and treatment of zika virus infection
MX2019010458A (es) 2017-03-03 2020-01-20 Rinat Neuroscience Corp Anticuerpos anti-gitr y metodos de uso de los mismos.
WO2018189611A1 (en) 2017-04-12 2018-10-18 Pfizer Inc. Antibodies having conditional affinity and methods of use thereof
RU2665790C1 (ru) 2017-04-17 2018-09-04 Закрытое Акционерное Общество "Биокад" Моноклональное антитело к pd-l1
US11236151B2 (en) 2017-04-25 2022-02-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies and methods for the diagnosis and treatment of Epstein Barr virus infection
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
WO2018215835A1 (en) 2017-05-26 2018-11-29 Novimmune Sa Anti-cd47 x anti-mesothelin antibodies and methods of use thereof
AU2018275359C1 (en) 2017-06-02 2022-02-03 Pfizer Inc. Antibodies specific for FLT3 and their uses
WO2019018629A1 (en) 2017-07-19 2019-01-24 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services ANTIBODIES AND METHODS FOR DIAGNOSING AND TREATING INFECTION WITH HEPATITIS B VIRUS
US20200354452A1 (en) 2017-09-29 2020-11-12 City Of Hope Cars and bispecific antibodies for treatment of mantle cell lymphoma
RU2698048C2 (ru) 2017-10-03 2019-08-21 Закрытое Акционерное Общество "Биокад" МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα
BR112020015641A2 (pt) 2018-02-01 2021-01-05 Pfizer Inc. Anticorpos específicos para cd70 e seus usos
IL310216A (en) 2018-03-05 2024-03-01 Janssen Biotech Inc Methods for treating Crohn's disease with a specific anti-IL23 antibody
EP3765005A4 (en) 2018-03-13 2022-02-23 The Regents of the University of California INHIBITORS OF INTEGRIN ALPHA 2 BETA 1 AND METHOD OF USE
US11203646B2 (en) 2018-03-14 2021-12-21 Novimmune Sa Anti-CD3 epsilon antibodies and methods of use thereof
CN108357203A (zh) * 2018-04-23 2018-08-03 广州市威顿彩印有限公司 一种彩印产线用转叶式干燥设备及其使用方法
WO2019213416A1 (en) 2018-05-02 2019-11-07 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies and methods for the diagnosis, prevention, and treatment of epstein barr virus infection
US20190345245A1 (en) 2018-05-11 2019-11-14 Janssen Biotech, Inc. Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
MX2020012607A (es) 2018-05-23 2021-01-29 Pfizer Anticuerpos especificos para gucy2c y sus usos.
WO2019224385A2 (en) 2018-05-24 2019-11-28 Glenmark Pharmaceuticals S.A. Combined bispecific antibody and immuno-oncology therapies
WO2019246494A1 (en) 2018-06-21 2019-12-26 Yumanity Therapeutics, Inc. Compositions and methods for the treatment and prevention of neurological disorders
MA52968A (fr) 2018-06-23 2021-04-28 Hoffmann La Roche Méthodes de traitement du cancer du poumon à l'aide d'un antagoniste de liaison à l'axe pd-1, d'un agent de platine et d'un inhibiteur de la topoisomérase ii
AU2019295855A1 (en) 2018-06-29 2021-01-28 City Of Hope CD6 targeted chimeric antigen receptors for treatent of certain autoimmune disorders
WO2020014306A1 (en) 2018-07-10 2020-01-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
EP3823611A1 (en) 2018-07-18 2021-05-26 Genentech, Inc. Methods of treating lung cancer with a pd-1 axis binding antagonist, an antimetabolite, and a platinum agent
WO2020016838A2 (en) 2018-07-18 2020-01-23 Janssen Biotech, Inc. Sustained response predictors after treatment with anti-il23 specific antibody
AU2019319822A1 (en) 2018-08-08 2021-03-18 Genentech, Inc. Use of tryptophan derivatives and L-methionine for protein formulation
US20210221864A1 (en) 2018-08-24 2021-07-22 City Of Hope Masked cytokine conjugates
WO2020061381A1 (en) 2018-09-19 2020-03-26 La Jolla Institute For Immunology Ptprs and proteoglycans in rheumatoid arthritis
AU2019342133A1 (en) 2018-09-21 2021-04-22 Genentech, Inc. Diagnostic methods for triple-negative breast cancer
CN113260626B (zh) 2018-11-05 2024-09-13 豪夫迈·罗氏有限公司 在原核宿主细胞中产生双链蛋白质的方法
WO2020104943A2 (en) 2018-11-20 2020-05-28 Janssen Biotech, Inc. Safe and effective method of treating psoriasis with anti-il-23 specific antibody
CA3137397A1 (en) 2019-04-19 2020-10-22 Chugai Seiyaku Kabushiki Kaisha Chimeric receptor that recognizes engineered site in antibody
AU2020279987A1 (en) 2019-05-23 2021-11-18 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
CA3142580A1 (en) 2019-06-03 2020-12-10 Janssen Biotech, Inc. Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis
AR119264A1 (es) 2019-06-05 2021-12-09 Genentech Inc Método para reutilización de cromatografía
CN114341187A (zh) 2019-07-12 2022-04-12 中外制药株式会社 抗突变型fgfr3抗体及其用途
CA3145278A1 (en) 2019-07-26 2021-02-04 Vanderbilt University Human monoclonal antibodies to enterovirus d68
US12098212B2 (en) 2019-08-12 2024-09-24 Purinomia Biotech, Inc. Methods and compositions for promoting and potentiating T-cell mediated immune responses through ADCC targeting of CD39 expressing cells
WO2021028752A1 (en) 2019-08-15 2021-02-18 Janssen Biotech, Inc. Anti-tfn antibodies for treating type i diabetes
US20230076643A1 (en) 2019-12-30 2023-03-09 City Of Hope Methods of making and using regulatory t cells and effector t cells having chimeric antigen receptors targeted to cd6, cd19, and/or an il-13r for treatment of autoimmune disorders and cancers
US20210277092A1 (en) 2020-02-11 2021-09-09 Vanderbilt University HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2)
WO2021195385A1 (en) 2020-03-26 2021-09-30 Vanderbilt University HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-GoV-2)
MX2022011892A (es) 2020-03-26 2022-10-18 Univ Vanderbilt Anticuerpos monoclonales humanos dirigidos contra el coronavirus 2 del sindrome respiratorio agudo grave (sars-cov-2).
WO2021205325A1 (en) 2020-04-08 2021-10-14 Pfizer Inc. Anti-gucy2c antibodies and uses thereof
MX2021015024A (es) 2020-04-28 2022-01-18 Univ Rockefeller Anticuerpos anti-sars-cov-2 ampliamente neutralizantes y métodos de uso de los mismos.
IL299039A (en) 2020-06-16 2023-02-01 Genentech Inc Methods and preparations for the treatment of triple-negative breast cancer
AU2021308586A1 (en) 2020-07-17 2023-03-02 Pfizer Inc. Therapeutic antibodies and their uses
WO2022098870A1 (en) 2020-11-04 2022-05-12 The Rockefeller University Neutralizing anti-sars-cov-2 antibodies
JP2024505636A (ja) 2021-01-15 2024-02-07 ザ ロックフェラー ユニバーシティー 抗ｓａｒｓ－ｃｏｖ－２中和抗体
WO2022159349A1 (en) 2021-01-20 2022-07-28 Oncoresponse, Inc. Immunomodulatory antibodies and uses thereof
BR112023018400A2 (pt) 2021-03-12 2023-12-12 Janssen Biotech Inc Método para tratamento de pacientes de artrite psoriática com resposta inadequada à terapia de tnf com anticorpo específico anti-il23
EP4305061A1 (en) 2021-03-12 2024-01-17 Janssen Biotech, Inc. Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody
AU2022241935A1 (en) 2021-03-22 2023-09-28 Novimmune S.A. Bispecific antibodies targeting cd47 and pd-l1 and methods of use thereof
US20220315655A1 (en) 2021-03-22 2022-10-06 Novimmune Sa Bispecific antibodies targeting cd47 and pd-l1 and methods of use thereof
US20240218057A1 (en) 2021-05-06 2024-07-04 The Rockefeller University Neutralizing anti- sars-cov-2 antibodies and methods of use thereof
IL312401A (en) 2021-10-29 2024-06-01 Janssen Biotech Inc Methods for treating Crohn's disease with a specific anti-IL23 antibody
AU2022383057A1 (en) 2021-11-05 2024-05-16 Abviro Llc Human broadly crossreactive influenza monoclonal antibodies and methods of use thereof
US20230151087A1 (en) 2021-11-15 2023-05-18 Janssen Biotech, Inc. Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
IL313021A (en) 2021-11-23 2024-07-01 Janssen Biotech Inc A method for treating ulcerative colitis with a specific anti-IL23 antibody
WO2023147399A1 (en) 2022-01-27 2023-08-03 The Rockefeller University Broadly neutralizing anti-sars-cov-2 antibodies targeting the n-terminal domain of the spike protein and methods of use thereof
CN114485122A (zh) * 2022-02-24 2022-05-13 广西青松木业有限公司 一种隧道式木材单板烘干生产线
AU2023236386A1 (en) 2022-03-18 2024-10-10 Evolveimmune Therapeutics, Inc. Bispecific antibody fusion molecules and methods of use thereof
WO2023187707A1 (en) 2022-03-30 2023-10-05 Janssen Biotech, Inc. Method of treating mild to moderate psoriasis with il-23 specific antibody
GB202204813D0 (en) 2022-04-01 2022-05-18 Bradcode Ltd Human monoclonal antibodies and methods of use thereof
AR128956A1 (es) 2022-04-01 2024-06-26 Genentech Inc Derivados de hidroxipropilmetilcelulosa para estabilizar polipéptidos
WO2023215498A2 (en) 2022-05-05 2023-11-09 Modernatx, Inc. Compositions and methods for cd28 antagonism
WO2023223265A1 (en) 2022-05-18 2023-11-23 Janssen Biotech, Inc. Method for evaluating and treating psoriatic arthritis with il23 antibody
US20240254234A1 (en) 2022-10-21 2024-08-01 Novimmune Sa PD-L1xCD28 BISPECIFIC ANTIBODIES FOR IMMUNE CHECKPOINT-DEPENDENT T CELL ACTIVATION
WO2024097639A1 (en) 2022-10-31 2024-05-10 Modernatx, Inc. Hsa-binding antibodies and binding proteins and uses thereof
US20240199734A1 (en) 2022-11-22 2024-06-20 Janssen Biotech, Inc. Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody
WO2024118866A1 (en) 2022-12-01 2024-06-06 Modernatx, Inc. Gpc3-specific antibodies, binding domains, and related proteins and uses thereof
WO2024173607A2 (en) 2023-02-14 2024-08-22 Evolveimmune Therapeutics, Inc. Combination of bispecific antibodies and chimeric antigen receptor t cells for treatment
WO2024206126A1 (en) 2023-03-27 2024-10-03 Modernatx, Inc. Cd16-binding antibodies and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1543585A (en) * 1923-03-24 1925-06-23 Heekin Can Company Synchronized press and oven conveyer
GB793216A (en) * 1956-02-18 1958-04-09 James Arthur Black Improvements in or relating to a method of and machine or apparatus for drying coated sheet stock
DE1222083B (de) * 1962-04-02 1966-08-04 Rank Xerox Ltd Einrichtung zum Transportieren von Papier- od. dgl. Blaettern

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
US8030023B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. Nucleic acid encoding DR5 antibodies and uses thereof
US8029783B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
US8409570B2 (en) 2005-02-02 2013-04-02 Genentech, Inc. Method of inducing apoptosis using anti-DR5 antibodies
US7674605B2 (en) 2006-06-07 2010-03-09 Bioalliance C.V. Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same
US8999702B2 (en) 2008-06-11 2015-04-07 Emd Millipore Corporation Stirred tank bioreactor
US8697386B2 (en) 2009-10-22 2014-04-15 Genentech, Inc. Methods and compositions for modulating hepsin activation of macrophage-stimulating protein
US9266948B2 (en) 2009-12-23 2016-02-23 Genentech, Inc. Anti-Bv8 antibodies and uses thereof
US9217048B2 (en) 2010-05-17 2015-12-22 Emd Millipore Corporation Stimulus responsive polymers for the purification of biomolecules
US8691918B2 (en) 2010-05-17 2014-04-08 Emd Millipore Corporation Stimulus responsive polymers for the purification of biomolecules
US9731288B2 (en) 2010-05-17 2017-08-15 Emd Millipore Corporation Stimulus responsive polymers for the purification of biomolecules
US8771966B2 (en) 2010-06-03 2014-07-08 Genentech, Inc. Immuno-PET imaging of antibodies and immunoconjugates and uses therefor
US9873742B2 (en) 2012-10-05 2018-01-23 Genentech, Inc. Methods for diagnosing and treating inflammatory bowel disease
US11091551B2 (en) 2012-10-05 2021-08-17 Genentech, Inc. Methods for diagnosing and treating inflammatory bowel disease

Also Published As

Publication number Publication date
DE2860970D1 (en) 1981-11-12
FR2413974B1 (ja) 1982-12-03
EP0003089A1 (fr) 1979-07-25
FR2413974A1 (fr) 1979-08-03

Similar Documents

Publication Publication Date Title
EP0003089B1 (fr) Séchoir pour feuilles imprimées par sérigraphie
CH675784A5 (ja)
CH402388A (fr) Appareil pour le façonnage d'articles à partir d'une feuille thermoplastique
EP0015314A1 (fr) Dispositif d'alimentation du papier sur une platine cylindrique tournante d'imprimante
BE1004555A3 (fr) Machine pour decouenner du lard.
EP0424290B1 (fr) Dispositif de positionnement d'un produit en forme de feuille souple
EP0780065A1 (fr) Dispositif d'assemblage de la tige et de la semelle d'une chaussure
FR2541562A1 (fr) Procede de greffage automatique de la vigne et machine comportant application de ce procede
EP0086867B1 (fr) Machine à étiqueter portative
EP0220967B1 (fr) Convoyeur de récipients
EP0578551B1 (fr) Perfectionnements aux machines d'impression, notamment aux machines de sérigraphie
CH642269A5 (fr) Frein a ski.
FR2575629A1 (fr) Dispositif de montage automatique sur un substrat d'elements de circuit du type puce
EP0391772A1 (fr) Appareil pour la fixation d'agrafes de jonction sur un tapis transporteur ou similaire
EP0274296A1 (fr) Procédé d'operculage automatique de récipients, tels que des gobelets, dispositif pour l'exécution de ce procédé et machine de conditionnement équipé de ce dispositif
EP0252844B1 (fr) Machine automatique pour le traitement d'un matériau en bande et notamment pour la découpe d'un tel matériau
FR2733491A1 (fr) Dispositif de sortie d'exemplaires imprimes d'un dispositif a roues a aubes
EP0219444B1 (fr) Machine de fendage de bois à cône fileté rotatif
EP0259235A1 (fr) Machine pour le prélèvement automatique de peaux ou similaires à partir d'une pile
FR2649086A1 (fr) Distributeur de supports souples
FR2766411A1 (fr) Mecanisme d'impression thermique
CH632712A5 (en) Labelling device, particularly for bottles
FR2477504A1 (fr) Dispositif pour le pliage et le collage de bandes adhesives sur des documents plats
EP0249568A1 (fr) Manipulateur de bobines de fil pour centrifugeuses
BE1001017A6 (fr) Procede pour fixer l'extremite libre d'un rouleau de matiere plastique et dispositif pour la mise en oeuvre de ce procede.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Designated state(s): BE CH DE GB IT LU NL SE

17P Request for examination filed
ITF It: translation for a ep patent filed
GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Designated state(s): BE CH DE GB IT LU NL SE

REF Corresponds to:

Ref document number: 2860970

Country of ref document: DE

Date of ref document: 19811112

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19811231

PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

26 Opposition filed

Opponent name: SVECIA SILKSCREEN MASKINER AB

Effective date: 19820218

PLAB Opposition data, opponent's data or that of the opponent's representative modified

Free format text: ORIGINAL CODE: 0009299OPPO

R26 Opposition filed (corrected)

Opponent name: LINDBLOM, ERIK J.

Effective date: 19820218

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 19831031

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 19831130

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 19831231

Year of fee payment: 6

PLBN Opposition rejected

Free format text: ORIGINAL CODE: 0009273

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: OPPOSITION REJECTED

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 19841221

Year of fee payment: 7

Ref country code: CH

Payment date: 19841221

Year of fee payment: 7

27O Opposition rejected

Effective date: 19840722

NLR2 Nl: decision of opposition
PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 19851231

Year of fee payment: 8

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Effective date: 19861231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Effective date: 19870701

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee
REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Effective date: 19871228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Effective date: 19871231

BERE Be: lapsed

Owner name: SILIUM S.F.A.R.L.

Effective date: 19871231

Owner name: DAVID BERNARD

Effective date: 19871231

GBPC Gb: european patent ceased through non-payment of renewal fee
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Effective date: 19880901

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19881117

EUG Se: european patent has lapsed

Ref document number: 78400265.1

Effective date: 19880912